Short Interest in Avacta Group Plc (OTCMKTS:AVCTF) Declines By 25.4%

Avacta Group Plc (OTCMKTS:AVCTF) was the recipient of a significant drop in short interest in March. As of March 31st, there was short interest totaling 94,410 shares, a drop of 25.4% from the March 15th total of 126,575 shares. Based on an average daily volume of 13,619 shares, the days-to-cover ratio is currently 6.9 days.

Avacta Group Stock Performance

OTCMKTS:AVCTF opened at $0.89 on Wednesday. Avacta Group has a 12-month low of $0.40 and a 12-month high of $1.11. The stock has a 50-day moving average price of $0.87 and a 200 day moving average price of $0.91.

Avacta Group Company Profile

Avacta Group plc is a UK-based biotechnology company specializing in the discovery, development and commercialization of Affimer® biotherapeutics and diagnostic reagents. The company’s proprietary Affimer platform uses small, engineered protein scaffolds that can be tailored to bind specifically to target molecules, offering an alternative to traditional antibodies. Avacta operates two core divisions: Avacta Therapeutics, which focuses on novel treatments in oncology and immune-related diseases, and Avacta Analytical, which develops reagents and point-of-care diagnostic tests.

In its diagnostics business, Avacta has applied the Affimer technology to lateral flow assays, most notably for rapid detection of viral pathogens such as SARS-CoV-2.